Michael biopic pulls $217 million in opening weekend, eclipsing records while critics remain unimpressed

The newly released biographical film about the late pop icon, titled simply Michael, entered its first weekend of exhibition by amassing a worldwide total of approximately $217 million, a sum that not only eclipses previous biopic openings but also demonstrates the commercial viability of nostalgia‑driven projects even when they are accompanied by a chorus of critical disapproval.

In North America alone the picture secured a staggering $97 million, a domestic figure that dwarfs the $120.4 million accrued internationally, thereby producing a combined opening that surpasses the $180.4 million worldwide debut of the 2023 blockbuster Oppenheimer and the $124 million record set by the 2018 Bohemian Rhapsody, positions which had hitherto defined the upper limits of the genre.

The film’s achievement is all the more remarkable given that its production was riddled with publicized scheduling conflicts, legal entanglements involving the estate of the subject, and a critical consensus that largely condemned its narrative choices, facts that one would expect to dampen audience enthusiasm yet apparently did not impede the considerable financial inflow generated by a marketing campaign heavily reliant on the estate’s authorized endorsement and the casting of the subject’s nephew, Jaafar Jackson, in the lead role.

This contradiction between critical reception and box‑office performance underscores a systemic tendency within the entertainment industry to prioritize brand recognition and pre‑existing fan bases over artistic merit, a tendency that is further reinforced by distribution strategies that allocate premium screen counts and expansive promotional resources to projects whose primary appeal lies in the commodification of a cultural icon rather than in innovative storytelling.

Consequently, the record‑setting debut of Michael may be read less as a triumph of cinematic craftsmanship and more as an illustration of how institutional mechanisms, from estate‑controlled licensing to theatrical scheduling practices, can effectively manufacture commercial success irrespective of the underlying quality of the product.

Published: April 27, 2026